Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first‐year report from Japan
-
- Kohei Kaku
- Department of Internal Medicine Kawasaki Medical School Okayama Japan
-
- Mohamed A. Eid
- Medical & Scientific Affairs Novo Nordisk Pharma Limited Tokyo Japan
書誌事項
- 公開日
- 2015-04-20
- 権利情報
-
- http://creativecommons.org/licenses/by-nc-nd/4.0/
- DOI
-
- 10.1111/jdi.12348
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>In Japan, insulin therapy is recommended for the treatment of type 2 diabetes mellitus either directly after diet, exercise and lifestyle improvements, or if the target for glycemic control is not achieved with other hypoglycemic agents. Insulin degludec is an ultra‐long‐acting insulin that was launched in Japan in 2013, having shown good efficacy and safety in its clinical development program. It has now been used in clinical practice for more than 1 year. During this time, clinicians and researchers have identified possible factors that could influence the decision as to which patients might be appropriate for insulin degludec treatment. In the present review, we describe how to initiate and manage insulin degludec therapy in routine clinical practice. We also discuss several important topics related to the use of insulin degludec, including patient selection, dosing, handling of bolus insulin, hypoglycemia and other potential safety considerations.</jats:p>
収録刊行物
-
- Journal of Diabetes Investigation
-
Journal of Diabetes Investigation 6 (6), 610-619, 2015-04-20
Wiley